Taltz Use In Pregnancy & Lactation

Women of childbearing potential: Women of childbearing potential should use an effective method of contraception during treatment and for at least 10 weeks after treatment.
Pregnancy: There is a limited amount of data from the use of ixekizumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/fetal development, parturition or post-natal development (see Pharmacology: Toxicology: Preclinical safety data under Actions). As a precautionary measure, it is preferable to avoid the use of Ixekizumab (Taltz) during pregnancy.
Breastfeeding: It is not known whether ixekizumab is excreted in human milk or absorbed systemically after ingestion. However, ixekizumab is excreted at low levels in the milk of cynomolgus monkeys. A decision should be made whether to discontinue breastfeeding or to discontinue Ixekizumab (Taltz) taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Fertility: The effect of ixekizumab on human fertility has not been evaluated. Animal studies do not indicate direct or indirect harmful effects with respect to fertility (see Pharmacology: Toxicology: Preclinical safety data under Actions).